Agendia was founded by Laura van 't Veer, René Bernards, Prof. Laura van 't Veer, PhD, Prof. Dr. René Bernards, PhD in 2003.

Who are Agendia's investors?

Agendia's investors include Korys, Forbion, Gilde Healthcare.

Where is Agendia headquartered?

Agendia is headquartered in Irvine, US.

Agendia

Irvine, US · Founded 2003 · 224 employees on LinkedIn · 4 known investors

Find your way into Agendia

396 people in our graph share verified history with the Agendia team — schools, employers, funds. One of them is your warm intro.

Diede Brunenunlockedknows René Bernards · together at NKI (overlapped)

knows the team · via NKI

knows the team · via The Netherlands Cancer Institute

×4knows the team · via Agendia

×2knows the team · via Whitehead Institute

×3knows the team · via Massachusetts General Hospital

Agendia develops genomic technology and diagnostic tests for breast cancer patients. The company applies genomic science to improve treatment outcomes and quality of life for cancer patients.

AI & Machine Learning Biotech Digital Health Medical Devices

Founders & leadership

Agendia was founded in 2003 by Laura van 't Veer, René Bernards, Prof. Laura van 't Veer, PhD, and Prof. Dr. René Bernards, PhD.

Laura van 't Veer Co-founderLaura van 't Veer is a molecular biologist and co-founder of Agendia who developed genomic diagnostic approaches for breast cancer treatment. Her research has examined tumor genetic profiling to guide treatment decisions, including leadership of the MINDACT clinical trial and work on the MammaPrint test now incorporated into major clinical guidelines.

René Bernards Co-founderRené Bernards holds a Ph.D. from the University of Leiden and trained at the Whitehead Institute under Robert Weinberg, studying oncogenes and tumor suppressor genes before holding faculty positions at Massachusetts General Hospital and Utrecht University and senior scientist roles at the Netherlands Cancer Institute. He co-founded Agendia in 2003, a genomics-based diagnostic company that developed the first microarray-based breast cancer diagnostic test, and his research has focused on genome-wide functional genetic screens to identify biomarkers of cancer drug response.

Prof. Laura van 't Veer, PhDChief Research Officer, Co-founder

Prof. Dr. René Bernards, PhDCo-Founder and Scientific Advisor

Mark R. StraleyCEO

Investors · 4

Koryslisted by KorysHalle · $5.4M

How we know: Korys's portfolio page · Not right? Tell us

ForbionreportedNaarden

How we know: a partner's Signal profile · Not right? Tell us

Gilde HealthcarereportedUtrecht · $1.1M – $55M

How we know: funding news · Not right? Tell us

Also in the syndicate · 1

Athyrium Capital Management

Founder mafia

3 people who came through Agendia went on to found or lead other companies.

Bastiaan van der BaanDirector Business DevelopmentFounded Lixte Biotechnology Holdings Laurie HeilmannMember of The Supervisory Board of DirectorsFounded Notable Ruby GadelrabCommercialization Strategy ConsultantFounded MDisrupt

In the news

Agendia Secures $35 Million Investment from Funds Managed by Athyrium Capital Management to Support Expanded Commercial Footprint in Rapidly Growing Markets and New Research Collaborations - Agendiaagendia.com · Jul 2018

Agendia Raises $65 Million in a Private Round of Equity Financingprnewswire.com · May 2012

Frequently asked questions

What does Agendia do?: Agendia develops genomic technology and diagnostic tests for breast cancer patients. The company applies genomic science to improve treatment outcomes and quality of life for cancer patients.
Who founded Agendia?: Agendia was founded by Laura van 't Veer, René Bernards, Prof. Laura van 't Veer, PhD, Prof. Dr. René Bernards, PhD in 2003.
Who are Agendia's investors?: Agendia's investors include Korys, Forbion, Gilde Healthcare.
Where is Agendia headquartered?: Agendia is headquartered in Irvine, US.